Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial-Reference-Cited by-同舟云学术

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

Published:2014-10-15 Issue:1 Volume:21 Page:49-59
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Di Cosimo Serena,Sathyanarayanan Sriram,Bendell Johanna C.,Cervantes Andrés,Stein Mark N.,Braña Irene,Roda Desamparados,Haines Brian B.,Zhang Theresa,Winter Christopher G.,Jha Sharda,Xu Youyuan,Frazier Jason,Klinghoffer Richard A.,Leighton-Swayze Ann,Song Yang,Ebbinghaus Scot,Baselga José

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer;International Journal of Molecular Sciences;2024-08-27

2. Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review;Frontiers in Pharmacology;2024-03-22

3. Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model;Frontiers in Oncology;2023-09-25

4. Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors;JAMA Network Open;2023-07-28

5. XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease;Breast Cancer Research;2023-06-12